ES2389625T3 - Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena - Google Patents

Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena Download PDF

Info

Publication number
ES2389625T3
ES2389625T3 ES97917185T ES97917185T ES2389625T3 ES 2389625 T3 ES2389625 T3 ES 2389625T3 ES 97917185 T ES97917185 T ES 97917185T ES 97917185 T ES97917185 T ES 97917185T ES 2389625 T3 ES2389625 T3 ES 2389625T3
Authority
ES
Spain
Prior art keywords
espa
coli
espb
enteropathogenic
rdec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97917185T
Other languages
English (en)
Spanish (es)
Inventor
B. Brett Finlay
Markus Stein
Brendan Kenny
Michael. S. Donnenberg
Li-Ching Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2389625T3 publication Critical patent/ES2389625T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
ES97917185T 1996-04-23 1997-04-23 Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena Expired - Lifetime ES2389625T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1599996P 1996-04-23 1996-04-23
US15999P 1996-04-23
PCT/CA1997/000265 WO1997040063A2 (en) 1996-04-23 1997-04-23 Pathogenic escherichia coli associated protein espa

Publications (1)

Publication Number Publication Date
ES2389625T3 true ES2389625T3 (es) 2012-10-29

Family

ID=21774805

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97917185T Expired - Lifetime ES2389625T3 (es) 1996-04-23 1997-04-23 Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena

Country Status (10)

Country Link
US (4) US6355254B1 (https=)
EP (1) EP0904288B1 (https=)
JP (3) JP2000511771A (https=)
KR (1) KR20000010667A (https=)
AU (1) AU2562897A (https=)
BR (1) BR9710433A (https=)
CA (1) CA2252372C (https=)
DK (1) DK0904288T3 (https=)
ES (1) ES2389625T3 (https=)
WO (1) WO1997040063A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
BR9710433A (pt) 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica
US6204004B1 (en) * 1997-03-21 2001-03-20 University Of Maryland, Baltimore Immunodiagnostic test for enterohemorrhagic Escherichia coli infection
US7208574B1 (en) 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
WO1999045136A1 (en) * 1998-03-05 1999-09-10 University Of British Columbia Methods for assaying type iii secretion inhibitors
US6342352B1 (en) 1998-04-24 2002-01-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of detecting shigella and shigella mxiM DNA
US6136542A (en) * 1998-05-13 2000-10-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
US6696249B1 (en) 1998-05-13 2004-02-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
WO2001073440A2 (de) * 2000-03-28 2001-10-04 Schebo Biotech Ag Nachweis von diarrhogenen e.coli-keimen
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli
BRPI0415816A (pt) 2003-10-31 2006-12-26 Univ British Columbia composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit
GB0411624D0 (en) * 2004-05-25 2004-06-30 Imp College Innovations Ltd Products and uses thereof
JP5151477B2 (ja) 2005-04-28 2013-02-27 日立金属株式会社 半導体磁器組成物とその製造方法
WO2008133659A2 (en) 2006-11-29 2008-11-06 Tufts University Eschericia coli mutants and methods of use thereof
WO2009032978A2 (en) * 2007-09-07 2009-03-12 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP2012522522A (ja) 2009-04-06 2012-09-27 ユニバーシティー オヴ サスカチュワン 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物
US20110229512A1 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
JP5714692B2 (ja) * 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｍｂａ−Ｉｎｓｔｉｔｕｔ Ｆｕｅｒｍｏｌｅｋｕｌａｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｇｍｂｈ Ｉｉｉ型分泌機構の阻害剤の同定方法
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15999A (en) 1856-10-28 Improved projectile for ordnance
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
BR9710433A (pt) * 1996-04-23 1999-10-05 Univ British Columbia Proteínas associada a escherichia coli patogênica

Also Published As

Publication number Publication date
US20060292180A1 (en) 2006-12-28
BR9710433A (pt) 1999-10-05
US20110003339A1 (en) 2011-01-06
CA2252372A1 (en) 1997-10-30
JP2010132698A (ja) 2010-06-17
CA2252372C (en) 2010-06-29
US20020115829A1 (en) 2002-08-22
JP5058106B2 (ja) 2012-10-24
WO1997040063A3 (en) 1998-03-26
US7078193B2 (en) 2006-07-18
DK0904288T3 (da) 2012-09-24
AU2562897A (en) 1997-11-12
JP2000511771A (ja) 2000-09-12
US8021861B2 (en) 2011-09-20
EP0904288B1 (en) 2012-06-13
JP2009022294A (ja) 2009-02-05
US6355254B1 (en) 2002-03-12
EP0904288A2 (en) 1999-03-31
US7214499B2 (en) 2007-05-08
KR20000010667A (ko) 2000-02-25
WO1997040063A2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
ES2389625T3 (es) Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena
KR20110102956A (ko) 세균성 발병력 인자들 및 그의 용도들
Watnick et al. Purification of Vibrio cholerae Fur and estimation of its intracellular abundance by antibody sandwich enzyme-linked immunosorbent assay
ES2333630T3 (es) Hp90: receptor de membrana anfitriona para bacterias patogenicas, codificadas por el gen tir bacteriano.
JP2009022299A (ja) 変異Ｓｈｉｇｅｌｌａｆｌｅｘｎｅｒｉ２ａ
WO1999045136A1 (en) Methods for assaying type iii secretion inhibitors
US5871951A (en) Compositions and methods for treatment of infection caused by Haemophilus influenzae and Streptococcus pneumoniae
AU740481B2 (en) Defining epitopes of the outer membrane protein CopB of moraxella catarrhalis
US6410703B1 (en) Identification of a vaccine candidate from an extraintestinal isolate of E. coli
US7759462B2 (en) Host receptor for pathogenic bacteria
WO1999045120A2 (en) Attenuation of bacteria: materials and methods relating thereto
MXPA98008795A (es) Proteina asociada con escherichia coli patogena
Newson The SseK effector proteins of Salmonella Typhimurium target host cell signaling proteins
KJERULF et al. Serological diagnosis of experimental Enterococcus faecalis endocarditis
CN1222937A (zh) 致病性大肠杆菌相关蛋白
Sal Periplasmic flagella of the spirochetes Borrelia burgdorferi and Brachyspira hyodysenteriae
Hiltke Molecular characterization of outer membrane proteins of Haemophilus ducreyi as immune targets
JP2004522945A (ja) スタフィロコッカス・アウレウス必須遺伝子及びそのコードされるタンパク質ｓｔａａｕ＿ｒ２に関連する組成物及び方法
MXPA96005692A (es) Metodos y reactivos para el tratamiento de artritis reumatoide